#ItsNotInYourHead

#ItsNotInYourHead is a campaign launched by Dr. Lori Brotto and the Women’s Health Research Institute to raise awareness about provoked vestibulodynia (PVD) and evidence-based psychological interventions for improving pain management.

PVD is pain experienced when contact is made with the area near the entrance to the vagina, known as the vulvar vestibule. This pain often occurs during sexual activity, but it can also be triggered by clothing, inserting tampons, pap tests, sitting, or any other touching sensations. Dr. Lori Brotto conducted research at the University of British Columbia with two groups of women living with PVD, treating one with mindfulness-based therapy, and the other with cognitive behavioural therapy. Both groups of women saw improvement in their ability to manage pain. Many women are unable to receive an accurate diagnosis since PVD does not manifest physically. This can lead to frustration, hopelessness, and feelings of isolation as they are led to believe that their pain is “all in their head”.

The #ItsNotInYourHead campaign launched October 6th, 2017 with a short video describing the condition and letting women know that their pain is real. To follow the campaign, follow @NotInYourHead17 on Twitter and Facebook. You can join the conversation about provoked vestibulodynia using the hashtags #ItsNotInYourHead and #PVD.

Metro Vancouver Study finds an association between South Asian Ethnicity and Risk of Vitamin B12 Deficiency during Pregnancy

Vitamin B12 (B12) sufficiency during pregnancy is essential for optimal maternal health and fetal and infant growth and development. Maternal B12 deficiency has been associated with poor pregnancy outcomes, such as preterm birth, low birth weight, intra-uterine growth restriction and neural tube defects, as well as poor cardiometabolic health and impaired cognitive development in the infant. Suboptimal B12 status has previously been reported in pregnant Canadian women. A secondary analysis study conducted by the research team of Dr Yvonne Lamers, Canada Research Chair in Human Nutrition and Vitamin Metabolism, aimed to determine B12 status and the prevalence of B12 deficiency in pregnant women in Metro Vancouver, using the more sensitive, combined measurement of a direct (plasma total B12) and functional (methylmalonic acid (MMA)) B12 indicator. The sample of the original cross-sectional study included 320 women with singleton pregnancies between their 20th and 35th weeks of gestation, with data collection between February 2009 and February 2010.

The prevalence of plasma total B12 concentration below 148pmol/L (reflecting B12 deficiency) and of concentrations between 148-220pmol/L (reflecting suboptimal B12 status) were 18% and 33%, respectively, in these 320 pregnant women of European, Chinese Asian, South Asian or other ethnicities. South Asian ethnicity was the strongest predictor of having plasma total B12 concentration reflecting B12 deficiency, with South Asian pregnant women having a 10x greater risk of B12 deficiency compared to European pregnant women. The odds of having elevated MMA concentrations (>220pmol/L) was 5x higher in South Asian compared to European pregnant women. Conversely, B12 supplement use decreased the risk of B12 deficiency by 69% in all pregnant women. A higher prevalence of B12 deficiency in South Asian pregnant women may be due to lower intake of animal source foods, the natural sources of dietary B12. Future research is underway to investigate the predictors of low B12 status in South Asian pregnant women. Overall, the study highlights the importance of determining B12 status early in pregnancy to allow for early intervention to prevent adverse maternal and fetal health outcomes.

Read the full study here.

WCE Patient Highlights


PATIENT HIGHLIGHTS OF THE WORLD
CONGRESS ON ENDOMETRIOSIS

1. What were the highlights of the conference for you?
I had the pleasure of volunteering at the conference which was, in itself, a highlight. It was helpful to see doctors as people without them measuring their words so carefully and just being open about how damaging this disease is. There was no sugarcoating, no roundabout answers, just truth.

Hearing their own frustrations with the lack of answers and hope that they could give helped me deal with my frustrations. It helped to know that they were in the same place as me: looking at this damage and trying to find a cure, or a biomarker to at least move one step closer to lessen the damage. Hearing them speak about how they longed to be able to give hope to their patients, how they cared for their patients and hated giving them generalizations and unknowns.

I felt like this week gave me tools to be able to forge ahead, it gave me the strength to keep fighting and advocating for myself, knowing that there are others advocating on my behalf out there. I was treated like a person, not as a patient, not as someone broken that they were going to try to fix, but just as another person looking for answers. The medical side of things was fascinating to me. It helped me understand what is going on inside of me. It helped to hear the statistics and research and be able to step back and look at it from a different, more removed point of view. One of the biggest highlights was getting a free textbook, Endometriosis: A Concise Practical Guide to Current Diagnosis and Treatment. I have been reading this little bits at a time and though some of it goes completely over my head, I have been learning so much about my body!

2. Did any presentations stand out to you?
I thoroughly enjoyed hearing anything Dr. Sawsan As-Sanie had to present. She spoke clearly, with passion about her subjects and also spoke about her patients as humans and not just as a subject or a number. There was a very good presentation on the value of Visanne as a medication to treat Endometriosis which I thought was very well done.

One of the best presentations for me was by Deborah Bush from New Zealand. She spoke about patient centred approaches to improve quality of life with passion and knowledge and is doing very good work where she is. It made me a little jealous of women who live there. I was able to hear Linda Giudice speak on the implications of delayed diagnosis for endometriosis. This is a subject that directly affects me after a 14 year delay in diagnosis. I appreciated much of what she had to say and found a lot of it very applicable and still hopeful.

3. Did you learn anything new about Endometriosis? If so, what?
I learned so much during my time and even more after. I was given tools and resources there that I didn’t know about before. I heard doctors passionately explain what their research goals were to relieve suffering and focus on higher quality of life. I learned the reasons why some foods make me feel better and some hurt me. It’s so much easier when I know why I’m told don’t do this or do that.

I learned why I feel pain so quickly and severely and how my brain actually looks differently on scans due to the long term pain I’ve had. I learned that there are some things I’m more prone to that my doctor wouldn’t have told me about such as certain cancers and different risks in pregnancy that the typical woman. But this knowledge is not defeating: it helps me prepare and keep an eye out for things in order to protect myself. Ignorance is not bliss: closing your eyes to possible negative things won’t stop them from happening. In my opinion, I’d rather be prepared than finding more damage too late.

Vaginal Microbiome Group Initiative

vogue

Principal Investigator: Dr. Deborah Money

Primary Contact: Zahra Pakzad, Research Coordinator, 604-875-2424 ext. 6379, zahra.pakzad@cw.bc.ca

About the study: The VOGUE study team is comprised of a diverse group of scientists and clinicians from across Canada who are using genomic methods to study the microbial ecosystem (microbiome) of the vagina in varying states of health and disease. The VOGUE research program comprises 5 sub-studies, each examining the vaginal microbiome of distinct clinical populations: healthy non-pregnant women, women living with HIV, women with recurrent vulvovaginitis, pregnant women at low risk for preterm birth, and pregnant women at high risk for preterm birth. The team is united in their goal of capitalizing on advances in genomic sequencing technology to analyze the composition, distribution, and function of vaginal microbes, and probe the links between these microbes and disease to guide the development of novel diagnostic tools and interventions to improve women’s health in Canada and around the world.

Why is this research important? The healthy vagina is host to millions of microorganisms, including many types of “good” bacteria that protect against invading pathogens, and help to promote healthy pregnancy. Until now, clinicians and scientists have had relatively unsophisticated tools at their disposal for studying this critically important ecosystem. It has only been with recent advances in genomic sequencing technology that researchers have been able to uncover and truly understand the sheer number and diversity of organisms that inhabit the vagina (the vaginal microbiome). From a single swab taken from the vagina, we are now able to sequence a section of the DNA from each type of bacteria present, and use this unique DNA “fingerprint” to identify them. As we move toward more sophisticated ways to diagnose and treat imbalances in the vaginal microbiome, this will allow us to develop more personalized and targeted interventions, in order to restore a microbiome that optimizes reproductive health in individual women. Ultimately, we hope our work will lead to significant breakthroughs in the health and well-being of women in Canada and around the world.

Study status: Recruitment is limited to the VOGUE 1B2 sub-study (women with recurrent vulvovaginitis). Recruitment for all other sub-studies is complete. Data analysis, manuscript development, and knowledge translation are ongoing.

Study results/publication:

Albert AY, Chaban B, Wagner EC, Schellenberg JJ, Links MG, van Schalkwyk J, Reid G, Hemmingsen SM, Hill JE, Money D, and the VOGUE Research Group. A study of the vaginal microbiome in healthy Canadian women utilizing cpn60-based molecular profiling reveals distinct Gardnerella subgroup community state types. PLoS One. 2015;10(8):e0135620.

Co-Investigators: Dr. Alan Bocking (University of Toronto), Dr. Sean Hemmingsen (National Research Council’s Plant Biotechnology Institute, Saskatchewan), Dr. Janet Hill (University of Saskatchewan), Dr. Gregor Reid (University of Western Ontario), Dr. Tim Dumonceaux (Agriculture and Agri-Food Canada, Saskatoon), Dr. Gregory Gloor (University  of Western Ontario), Dr. Matthew Links (Agriculture and Agri-Food Canada, Saskatoon), Dr. Kieran O’Doherty (University of Guelph), Dr. Patrick Tang (Sidra Medical and Research Center), Dr. Julie van Schalkwyk (University of British Columbia), Dr. Mark Yudin (University of Toronto).

Funded by: Canadian Institutes of Health Research (CIHR) and Genome BC

Advances in Screening and Prevention in Reproductive Cancers (ASPIRE)

Advances in Screening and Prevention in Reproductive Cancers (ASPIRE)

Principal Investigator: Dr. Gina Ogilvie

Primary Contact: Heather Pedersen, Research Coordinator, 604-707-2424 x5473, Heather.pedersen@cw.bc.ca

About the study: ASPIRE is a women’s health initiative using innovative models and technologies to improve access to reproductive health in low income settings. Since 2007, ASPIRE has conducted various community-based cervical cancer screening initiatives in Kampala, Uganda using self collection-based HPV testing. The project takes an integrated health services approach to address cervical cancer along other reproductive health issues including sexually transmitted infections and HIV.

Why is this research important? Cervical cancer, despite being almost entirely preventable, remains a leading cause of death among women in low and middle income countries largely due to the absence of screening programs in these regions. Cost-effective and acceptable tools are needed to improve access in low income settings. By integrating cervical cancer and reproductive health screening with routine HIV services, the health of vulnerable women can be protected while most effectively utilizing resources.

Study Status: 1) Randomized controlled trial comparing HPV self collection vs VIA in Kampala: complete; 2) Integration of cervical cancer screening with HIV services: under development; 3) Reproductive health & pregnancy outcomes in adolescents: under development.

Study results/publications:

Moses E, Pedersen HN, Mitchell SM, Sekikubo M, Mwesigwa D, Singer J, Biryabarema C, Byamugisha JK, Money DM, Ogilvie GS. Uptake of community-based, self-collected HPV testing vs. visual inspection with acetic acid for cervical cancer screening in Kampala, Uganda: Preliminary results of a randomized controlled trial. Trop Med Int Health. 2015; 20(10):1355-67.

Teng FF, Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JK, Steinberg M, Money DM, Ogilvie GS. Understanding the role of embarrassment in gynaecological screening: a qualitative study from the ASPIRE cervical cancer screening project in Uganda. BMJ Open 2014;4:4 e004783.

Mitchell SM, Sekikubo M, Biryabarema C, Byamugisha JJ, Steinberg M, Jeronimo J, Money DM, Christilaw J, Ogilvie GS. Factors associated with high-risk HPV positivity in a low-resource setting in sub-Saharan Africa. Am J Obstet Gynecol 2014 Jan;210(1):81.e1-7.

Ogilvie G S, Mitchell S, Sekikubo M, Biryabarema C, Byamugisha J, Jeronimo J, Miller D, Steinberg M, Money D M. Results of a community-based cervical cancer screening pilot project using human papillomavirus self-sampling in Kampala, Uganda. Int J Gynaecol Obstet 2013; 122 (2): 118–123.

Mitchell S, Ogilvie G, Steinberg M, Sekikubo M, Biryabarema C, Money D. Assessing women’s willingness to collect their own cervical samples for HPV testing as part of the ASPIRE cervical cancer screening project in Uganda. Int J Gynaecol Obstet 2011;114(2):111-115.

Co-Investigators: Deborah Money, Jan Christilaw, Josaphat Byamugisha, Sheona Mitchell, Angela Kaida, Ashley Roberts, Curren Warf, Patricia Spittal

Funded by: CIHR, CFRI, BCCDC Foundation, UBC, BC Women’s Foundation

Partners: University of British Columbia, Makerere University, BCCDC

Websites:

http://www.aspireafrica.ca/aspire/

WelTelOAKTREE: Text Messaging to Support Patients with HIV/AIDS in British Columbia

WelTelOAKTREE: Text Messaging to Support Patients with HIV/AIDS in British Columbia

Principal Investigator: Dr. Melanie Murray

Primary Contact: Evelyn Maan, Research Program Manager, 604-767-5044, emaan@cw.bc.ca

About the study: WelTel Oak Tree is a study that enrolled 80 HIV+ individuals from the Oak Tree Clinic at BC Women’s Hospital. Participants received a cell phone and/or unlimited text messaging capability if they did not have it already, and for one year received a weekly text message stating “How are you”. Participant problems and non-responses were followed up by a nurse. Data on demographics, CD4 counts, HIV viral loads, HIV medication adherence and attendance at appointments were collected for the year prior to the intervention and during the intervention for comparison. Data assessing quality of life was also collected at three points during the one year study period. Cost effectiveness and cost benefit of the intervention were looked at to assess feasibility of transferring the intervention to a programmatically funded facet of patient care.

Why is this research important? In Canada, around 65,000 people are living with HIV/AIDS, approximately 14,300 of whom are women. AntiRetroviral Therapy (ART) has led to enormous improvements in the health and survival of individuals with HIV. Moreover, by decreasing the amount of virus circulating in the body (viral load), HAART offers the possibility of treatment as a preventative measure. However, high levels of engagement in care, timely initiation of ARVs, and adherence to medication are required to maximize the benefits of HAART in order to prevent resistance, progression to AIDS, transmission or mortality. Unfortunately, engagement in ongoing HIV care can be poor, with one study from the United States (US) showing only 52% retention in care over 1 year. Further, adherence among high-risk populations is low, with women being less adherent partly due to their role as care providers for children and partners, potential abuse in partner relationships, fear of stigma, homelessness, and concerns regarding side effects. Conversely, active drug use (especially cocaine), lack of social supports, and depression are just a few of the variables that affect both men and women alike. Current methods of engagement in care have failed to overcome these barriers to adherence, which makes finding an effective adherence intervention critically important. Mobile health (mHealth), the use of mobile phone technology to deliver health care, is an emerging area of disease management that can assist in patient adherence to prolonged chronic treatment regimens and monitoring of care. A randomized controlled trial (WelTelKenya1), conducted by Dr. Richard Lester et. al, tested the clinical effectiveness of text message support for HIV treatment adherence in Kenya. WelTelKenya1, of which 67% were women, showed that patients receiving text message support had significantly higher rates of treatment adherence and viral suppression than patients who received standard care alone. In Canada, cell phone penetration exceeds 70% and is expected to reach 100% within the next decade. The WelTel system offers a clinical management model that can be carried out using standard services offered by cellular network providers with minimal additional infrastructure and is both flexible and scalable.

Study status: The study is no longer enrolling participants. Data analysis and manuscript preparation is underway.

Study results/publication:

Mean ART adherence improved from 61.7% to 68.3% (p<0.0001), and median population HIV log10VL declined by 0.70 log (p=0.007) from pre-intervention to intervention years.

Median VL decline for responders (response rate ≥50%) was 1.03 log (vs. 0.39 log, p=-.03), and adherence increase 13.7% (vs. 0.8%, p=0.008) versus non-responders (response rate <50%).

Managing “problem” responses required 53 minutes of Health Care Practitioner time per high-risk, vulnerable participant enrolled per year, for a cost per patient of $45.20.

Total intervention cost (including phones, plans, staff time) was $375.74 per patient per year.

Friesen K, Qiu AQ, Goktepe O, Maan EJ, Pick N, Alimenti A, Kestler M, Money D, Lester R, Murray MCM. Weekly text-messaging (Weltel) to engage vulnerable HIV+ populations: It works, what does it cost? (Oral Presentation, 25th Annual CAHR Conference, Winnipeg, MB.  May 12-15, 2016).

Friesen K, Qiu A, Goktepe O, Maan EJ, Pick N, Alimenti A, Kestler M, Smillie K, Money D, Lester R, Murray MCM and the WelTel OAKTREE Study Team. mHealth to Improve Health:  Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load in a Canadian Context: WelTel OAKTREE.” (Oral presentation), The 6th International Workshop on HIV and Women, Boston, February 21-22, 2016.

Murray, MCM, Friesen K, O’Shaughnessy S, Albert A, Maan EJ, Pick N, Alimenti A, Kestler M, Smillie K, Money D, Lester R, and the WelTel OAKTREE Study Team.  mHealth to Improve Health:  Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load in a Canadian Context: WelTel OAKTREE. (Poster Presentation), International AIDS Society Meeting, July 19-22, 2015. Abstract WEPED849, http://www.ias2015.org/WebContent/File/IAS_2015__MED2.pdf.

Friesen K, O’Shaughnessy S, Maan EJ, Makela N, Pickering B, Lester R, Pick N, Murray M.   How R U?  WelTelOAKTREE: Text messaging and nursing support to improve care for HIV positive patients taking antiretroviral therapy (cART) in British Columbia.  (Oral Presentation), 2014 Canadian Association of Nurses in AIDS Care (CANAC) Conference, April 24-26, 2014.

Co-Investigators: Dr. Ariane Alimenti, Karen Friesen, Dr. Richard Lester, Dr. Deborah Money, Dr. Neora Pick, and Dr. Laura Sauve.

Funded by: Gilead Sciences Inc. and Bristol-Myers Squibb

Prospective study of an interdisciplinary pelvic pain & endometriosis clinic (Etiology of dyspareunia in endometriosis)

Prospective study of an interdisciplinary pelvic pain & endometriosis clinic: Etiology of dyspareunia in endometriosis

Principal Investigator: Dr. Paul Yong

Primary Contact: Heather Noga, Research Coordinator, WHRI, 604-875-2424 ext 4924, Heather.Noga@cw.bc.ca

About the study: BC Women’s Centre for Pelvic Pain and Endometriosis is a tertiary referral centre in British Columbia dedicated to managing chronic pelvic pain (CPP) and endometriosis. The Centre offers a unique interdisciplinary approach that includes pain education workshops, pelvic floor physiotherapy, counselling, and medical and surgical management. The purpose of this study is to prospectively collect data from patients at the clinic to investigate long-term patient outcomes, and the etiology and treatment of CPP. Participants in the study will have their clinical intake questionnaires, physical exam, surgery, and pathology data included in the research and answer follow-up questionnaires at 6 months and 1-5 years.

Why is this research important? Chronic pelvic pain (CPP) (pelvic pain that lasts at least 3-6 months in duration) affects 15% of reproductive-aged women. It is a condition that can involve many physical, psychological, and behavioural consequences and have a devastating impact on quality-of-life. One of the most common origins of CPP is endometriosis, a condition in which endometrial tissue that usually lines the uterus grows outside of the uterus. However, pelvic pain may also result from numerous other gynaecological, musculoskeletal, gastrointestinal, or urological conditions, and can be difficult to manage. Therefore, there is benefit to an interdisciplinary approach in the management of CPP compared to standard treatment.

Study status: Recruitment, data collection, data analysis, and manuscript development is ongoing.

Who can participate: All patients referred for chronic pelvic pain and/ or endometriosis to the BC Women’s Centre for Pelvic Pain and Endometriosis.

Study results/publications:

Yosef, A., Allaire, C., Williams, C., Ahmed, G., Al-Hussaini, T., Abedellah, M., Wong, W., Lisonkova, S., Yong, P. (2016). Multifactorial contributions to the severity of chronic pelvic pain in women. American Journal of Obstetrics & Gynecology, epub ahead of print.

Co-Investigators: Dr. Catherine Allaire, Dr. Christina Williams, Dr. Mohamed Bedaiwy.

Funded by: Canadian Institutes of Health Research (CIHR), Vancouver Coastal Health Research Institute (VCHRI), University of British Columbia (UBC), Women’s Health Research Institute (WHRI).

Clinic website: http://www.womenspelvicpainendo.com/

Clinic page on research: http://www.womenspelvicpainendo.com/research/

Research Newsletter:

October 2016 Research Newsletter

Endometriosis – Determinants of Oncogenesis (ENDO-ONC) Full Scale Study

Endometriosis – Determinants of Oncogenesis (ENDO-ONC) Full Scale Study

Principal Investigator: Dr. Paul Yong

Primary Contact: Heather Noga, Research Coordinator, 604-875-2424 ext 4924, Heather.Noga@cw.bc.ca 

About the study: The aim of this study is to determine whether there are unique genetic changes in endometriosis that may play a role in malignant transformation to ovarian cancer or in the symptoms of pelvic pain and infertility. This will be done by comparing surgical tissue samples from women with endometriosis to women without endometriosis.

Participants in this study agree to provide for research purposes: a saliva sample, tissue removed from their surgery, endometrial biopsy (a sample from the lining of the uterus – only if a sample is not already being removed for clinical purposes).

Why is this research important? Endometriosis affects 10% of reproductive aged women, causes pain and infertility, and is now known to also be associated with ovarian cancer. Studying gene mutations and expression changes in surgical tissue samples of women with or without endometriosis will help us understand how it can lead to pain, infertility, ovarian cancer, and other associated symptoms.

Study status: Recruitment and data collection is ongoing.

Who can participate: You have (or are suspected to have) endometriosis OR another benign gynaecological condition, You have chosen surgical treatment.

Co-Investigators: Dr. Catherine Allaire, Dr. Christina Williams, Dr. Mohamed Bedaiwy, Dr. Jessica McAlpine, Dr. David Huntsman.

Funded by: Canadian Institutes of Health Research (CIHR), Canadian Cancer Society Research Institute (CCSRI), Women’s Health Research Institute (WHRI)

Partners: Ovarian Cancer Research Group (OvCaRe), Centre for Translational and Applied Genomics (CTAG).

Clinic website: http://www.womenspelvicpainendo.com/

Clinic Research Page: http://www.womenspelvicpainendo.com/research/

Does a Women’s Heart Center Change Clinical Outcomes?

Does a Women’s Heart Center Change Clinical Outcomes?

Principal Investigator: Dr. Tara Sedlak

Primary Contact: Emma Branch, Research Assistant, WHRI, 604-875-2424 ext 4796, Emma.Branch@cw.bc.ca

About the study: This study has two aims: firstly, to create a database of patients attending the VGH/BCWH Women’s Heart Center (WHC) to facilitate the ability of future investigators to conduct research on a number of different of issues surrounding women and heart disease. The second aim is to examine whether attendance at a WHC improves outcomes of patients with heart disease or at risk for heart disease. We will collect clinical information and some basic demographic information and store this in a de-identified database. We will also ask participants to complete a total of 4 questionnaires over a 5 year period.

Why is this research important? It is not yet known whether specialized care centers like the Women’s Heart Center improves outcomes in women compared to usual care. Through this study we hope to better understand how gender specific care can impact the outcome for woman with a range of different cardiac conditions.

Study status: Ethics approval in progress.

Who can participate? Any woman who is being seen within the Women’s Heart Center at Vancouver General Hospital and/or BC Women’s Hospital will be invited to participate in this study who is fluent in English.

Co-Investigators: Natasha Prodan-Bhalla, Dr. Karin H. Humphries.

CARMA-2-CORE

Mitochondrial and Telomere Studies in a Prospective Cohort AND Measuring Mitochondrial Aging, Application to HIV Infection and Therapy AND Cellular Aging and HIV Comorbidities in Women and Children

Principal Investigator: Dr. Helene Cote

Primary Contact: Evelyn Maan, Research Program Manager, 604-875-2000 ext. 2463, emaan@cw.bc.ca

About the study: CARMA-2-CORE is studying the effects of HIV and anti-HIV medications on cellular aging among children and adults living with, or exposed to HIV. As people with HIV are living longer, there is increasing evidence that HIV may cause a type of “early aging”.  CARMA-2-CORE is trying to better understand the impact of HIV and the anti-HIV medications on aging by looking at two markers of cellular aging: the length of DNA at the ends of chromosomes (“telomeres”) and the energy producing parts of the cell (“mitochondrial DNA”).

Why is this research important? As people with HIV are now living much longer, it is important to better understand the ways in which HIV or anti-HIV medications may contribute to the aging process. Additionally, there is a shortage of research in the field of HIV on the impact of anti-HIV medications in women and in children, making the CARMA-2-CORE study very important.

Study status: Recruiting

Who can participate: 

CARMA-2-CORE is currently actively recruiting women and children living with or exposed to HIV. CARMA-2-CORE is particularly looking for women and girls who fit the following criteria:

Age Misc.
12+ who have had their first menstrual period Fasting for at least 12 hours
19+ Have a scheduled Bone Density at BC Women’s Hospital

CARMA-2-CORE is also recruiting women and children who are not living with HIV, to act as study controls.  CARMA-2-CORE is particularly looking for women who fit the following criteria:

Ethnicity Age
Aboriginal/Indigenous 20-25

35-40

African/Caribbean/Black 15-60+
Caucasian/White 40-60+

Study results/publications: 

Zanet D, Thorne A, Singer J, Maan E, Sattha B, Pick N, Murray M, Money D, Cote H. Shorter leukocyte telomere length in HIV-infected individuals is unrelated to antiretroviral treatment or time since HIV diagnosis. Clin Infect Dis. 2014 May;58(9):1322-32. doi: 10.1093/cid/ciu051. Epub 2014 Jan 22. CA (IF 9.416, ranked 2/70 among Infectious Disease journals; Citations 7, 10/2015).

Zanet, D.L., Thorne, A., Singer, J., Maan, E.J., Sattha, B., Le Campion, A., Soudeyns, H., Pick, N., Murray, M., Money D,M,, Côté, H.C. (2014). Association between short leukocyte telomere length and HIV infection in a cohort study: No evidence of a relationship with antiretroviral therapy. CIHR Emerging Team Grant on HIV Therapy and Aging: CARMA. Clin Infect Dis 58(9):1322-32. doi: 10.1093/cid/ciu051. Epub 2014 Jan 22.

Côté HC, Soudeyns H, Thorne A, Alimenti A, Lamarre V, Maan EJ, Sattha B, Singer J, Lapointe N, Money DM, Forbes J; CIHR Emerging Team in HIV therapy, aging (CARMA), Wong J, Bitnun A, Samson L, Brophy J, Burdge D, Pick N, van Schalkwyk J, Montaner J, Harris M, Janssen P.  Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia.  PLoS One. 2012;7(7):e39266. Epub 2012 Jul 16

Co-Investigators: Dr. Neora Pick, Dr. Deborah Money, Dr. Melanie Murray, Dr. Ariane Alimenti.

Funded by: CIHR

Partners: Positive Women’s Network (PWN), Canadian Multicentre Osteoporosis Study (CaMOS)

Consent forms:

CARMA-2 Participant Consent form

CARMA-2 Control Consent Form